Our patron 

HRH Prince Charles, The Prince of Wales 

The Prince of Wales became patron of International Health Partners in 2005, shortly after we began our work. Over the years, he has attended our events, met our staff and spent time with our partners. We have benefited from our Patron’s extensive international networks as he has connected us to other global health actors. 

Continuing to renew his patronage, HRH The Prince of Wales remains among our most dedicated supporters and will be central to our 15th Anniversary Celebrations. 

 

Our board  

The board of International Health Partners plays a valuable role in overseeing our work. The board meets four times a year and their work is supported by several committees resourced by board members and other volunteers.  

The Board is made up of trustees and members. Trustees are:  

  • Peter O'Driscoll, Chair 
  • Helen Leighton (healthcare executive and coach) 
  • Barbara Brese (pharmacist and healthcare consultant)
  • Simon Howard (director, Agape Media) 
  • Wei-Lynn Lum (advisory lawyer, government legal department) 
  • Nigel Pearson (GP and international health adviser) 
  • Ian Walker (managing director, Johnson & Johnson) 
  • Glyn Williams (chartered accountant) 

Members  

  • Peter Ballard (healthcare executive) 
  • Professor Raman Bedi (chair, Global Child Dental Fund) 
  • Viscount Crispin Brentford 
  • Andrew Russell (chartered accountant) 
  • Professor The Lord McColl (chair, Mercy Ships UK) 

Our ambassadors  

International Health Partners has two (unpaid) ambassadors in the healthcare industry, who play an essential role in representing our interests and promoting our work in specialist fields. Ambassadors endorse us, open doors, and make useful introductions we are very grateful for the work they do.  

Professor Richard Barker

Richard has been associated with International Health Partners from its foundation and is the immediate past chairman. He is passionate about advancing biomedical innovation and about accelerating and spreading access to the fruits of this innovation to patients worldwide.

He is Founding Director of New Medicine Partners, a global firm assisting public and private sector organisations to accelerate the worldwide development and adoption of precision medicine. He also founded the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), a major UK academic initiative aimed at bringing biomedical advances more rapidly and affordably to patients. He is chairman of the South London Health Innovation Network and of the corresponding Genomic Medicine Centre. He also chairs Kvatchii, a digital health company bringing cardiovascular health improvement to India and other middle income economies. He is a board member of Image Analysis, a UK company using MRI to quantify the impact of therapy on disease and of Celgene, a major US-based bio-therapeutics company.

His 30-year career in healthcare has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. The senior roles he has held include: Director General of the Association of the British Pharmaceutical Industry, General Manager of Healthcare Solutions for IBM, Chief Executive of Chiron Diagnostics and head of McKinsey’s European healthcare practice.

His book on the future of healthcare ‘2030 - The Future of Medicine: Avoiding a Medical Meltdown’ and his second book ‘Bioscience – lost in translation?’ are published by Oxford University Press. 

 

Dr James Burt 

Executive Vice President, EMENAAccord Healthcare 

James has more than 20 years of experience in the pharmaceutical industry, predominantly in the generics and biosimilar sector. He has held commercial, business development and general management roles in the UK, Europe and globally. James has a bachelor’s degree in chemical and biochemical engineering, and D.Phil in chemical engineering, both from the University of Birmingham.  

James joined Accord in 2010 and currently leads its operations in the EMENA region. As part of this, he is developing and delivering strategy to improve people’s access to high-quality, affordable medicine. Over the last eight years, Accord has grown from fewer than 50 employees to more than 1,400 people in 25 different countries. 

 

Through International Health Partners, our medicines reach and help some of the most vulnerable people in the world, whose access to treatment is very limited. IHP does important work and we are honoured to be a part of it.” Dr James Burt, IHP Ambassador and Executive Vice President, EMENA, Accord Healthcare